Market 2026 sees Vonvendi or Veyvondi expanding with hemophilia therapy demand

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Much Is The Vonvendi Or Veyvondi Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

Historical growth was primarily driven by a rise in the diagnosis rates of von Willebrand disease, the availability of recombinant protein therapies, enhanced clinical awareness of bleeding disorders, the expansion of hospital-based hematology services, and the regulatory clearances granted for rVWF products.

Anticipated growth during the forecast period is driven by a heightened emphasis on tailored therapies for rare diseases, increased capital allocation towards recombinant biologics, the broadening availability of at-home infusion treatments, the expanding reach of specialty pharmacies, and innovations in protein engineering techniques.

Prominent trends for the upcoming period involve a surge in the application of recombinant plasma-free treatments, the increasing uptake of precision therapies for bleeding disorders, a heightened inclination towards immediate bleeding control solutions, the extended reach of specialty pharmacy networks, and a greater emphasis on individualized hematology services.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20450&type=smp

What Drivers Are Influencing The Vonvendi Or Veyvondi Market?

The rising number of clinical trials is projected to fuel the expansion of the vonvendi or veyvondi market in the future. These research studies assess the safety, effectiveness, and possible side effects of novel therapies, drugs, or medical devices. The increase in clinical trials is driven by progress in medical research and technology, a greater occurrence of chronic and complex conditions, and an aging global populace seeking new treatments. Clinical trials bolster vonvendi or veyvondi by offering robust scientific proof of their safety and effectiveness, facilitating regulatory clearance, building confidence among medical professionals and patients, and establishing pathways for improved treatment methods and wider availability for managing von Willebrand disease. For example, in December 2024, a report from the Association of the British Pharmaceutical Industry, a UK-based non-profit organization, indicated that the number of industry clinical trials started saw a small rise from 411 in 2022 to 426 in 2023, reflecting a minor upturn after several years. Consequently, the expanding volume of clinical trials is propelling the growth of the vonvendi or veyvondi market.

What Major Segment Divisions Exist Within The Vonvendi Or Veyvondi Market?

The vonvendi or veyvondi market covered in this report is segmented –

1) By Indication: Von Willebrand Disease Type 1, Von Willebrand Disease Type 2, Von Willebrand Disease Type 3

2) By Distribution Channel: Hospitals, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies

3) By End User: Adults, Pediatrics, Geriatric Patients

How Are Trends Shaping The Direction Of The Vonvendi Or Veyvondi Market?

Companies operating within the von Willebrand factor replacement market are prioritizing technological advancements, particularly through expanding indications and managing the regulatory lifecycle. This includes submitting and executing supplemental regulatory filings, supported by comprehensive clinical and real-world evidence, to extend treatments to prophylactic and pediatric applications. Indication expansion and regulatory lifecycle management involve a coordinated set of clinical, regulatory, and evidentiary activities, such as pivotal or extension trials, generation of real-world evidence, priority-review engagements, and updated safety-monitoring frameworks. These enable a product to transition from narrower approvals, often limited to adults or on-demand use, to broader routine prophylaxis and pediatric indications, thereby increasing the clinically eligible population and altering treatment paradigms. For instance, in September 2025, Takeda Pharmaceutical Company Limited, a global biopharmaceutical company headquartered in Japan, announced that the U.S. Food and Drug Administration had approved a supplemental Biologics License Application (sBLA) for VONVENDI. This expanded its indication to include routine prophylaxis for reducing the frequency of bleeding episodes in adults with all types of von Willebrand disease (including types 1 and 2), and to permit on-demand and perioperative management of bleeding in pediatric patients. This broadened approval extends the therapy’s authorized usage across more patient groups, strengthens its position as a recombinant VWF option for both adults and children, and creates new opportunities for prophylactic treatment strategies that can decrease bleeding frequency and improve patient quality of life.

Which Companies Are Leading Innovation In The Vonvendi Or Veyvondi Market?

Major companies operating in the vonvendi or veyvondi market are Takeda Pharmaceutical Co. Ltd.

Read the full vonvendi or veyvondi market report here:

https://www.thebusinessresearchcompany.com/report/vonvendi-or-veyvondi-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Vonvendi Or Veyvondi Market?

North America was the largest region in the vonvendi or veyvondi market in 2025. The regions covered in the vonvendi or veyvondi market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Vonvendi Or Veyvondi Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20450&type=smp

Browse Through More Reports Similar to the Global Vonvendi Or Veyvondi Market 2026, By The Business Research Company

Veterinary Pharmaceuticals Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-pharmaceuticals-global-market-report

Veterinary Pharmaceuticals Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-pharmaceuticals-global-market-report

Alternative Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/alternative-finance-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795